Novavax Shares Face Mounting Survival Pressure
Published on 11/24/2025 at 06:33 | Redaktion boerse-global.de
Novavax finds itself in a critical battle for corporate survival. The biotech firm’s stock is attempting to stabilize following a severe seven-day decline, caught between conflicting forces: a profitability timeline now pushed to 2028 and escalating demands from activist investors. The central question for market participants is whether Novavax can engineer a recovery or faces irreversible decline.
External pressure is intensifying as management pursues its long-term turnaround strategy. Major shareholder Shah Capital is aggressively pushing for the exploration of strategic alternatives, expressing clear dissatisfaction with the company’s commercial execution and what it terms the “slow adoption” of the protein-based vaccine.
The activist investor’s demands point toward nothing Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
